ibrutinib - Profile

What are the generic sources for ibrutinib and what is the scope of patent protection?

Ibrutinib is the generic ingredient in two branded drugs marketed by Zydus Lifesciences and Pharmacyclics Llc, and is included in four NDAs. There are fifty-six patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Ibrutinib has four hundred and ninety patent family members in fifty countries.

There are six tentative approvals for this compound.

Summary for ibrutinib

International Patents:	490
US Patents:	56
Tradenames:	2
Applicants:	2
NDAs:	4
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ibrutinib

Generic filers with tentative approvals for IBRUTINIB

Applicant	Application No.	Strength	Dosage Form
		140MG	CAPSULE;ORAL
		140MG	CAPSULE;ORAL
		560MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for IBRUTINIB

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
IMBRUVICA	Capsules	ibrutinib	70 mg	205552	1	2018-12-14
IMBRUVICA	Tablets	ibrutinib	280 mg and 420 mg	210563	1	2018-12-14
IMBRUVICA	Tablets	ibrutinib	560 mg	210563	1	2018-11-05
IMBRUVICA	Capsules	ibrutinib	140 mg	205552	8	2017-11-13

US Patents and Regulatory Information for ibrutinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Lifesciences	IBRUTINIB	ibrutinib	CAPSULE;ORAL	211344-001	Mar 31, 2021		DISCN	No	No
Zydus Lifesciences	IBRUTINIB	ibrutinib	CAPSULE;ORAL	211344-002	Mar 31, 2021		DISCN	No	No
Pharmacyclics Llc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No	11,672,803
Pharmacyclics Llc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No	10,004,746*PED				Y
Pharmacyclics Llc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No	7,514,444*PED				Y
Pharmacyclics Llc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No	8,008,309*PED				Y
Pharmacyclics Llc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No	8,476,284*PED				Y

EU/EMA Drug Approvals for ibrutinib

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Janssen-Cilag International NV	Imbruvica	ibrutinib	EMEA/H/C/003791IMBRUVICA as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).IMBRUVICA as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. IMBRUVICA in combination with rituximab is indicated for the treatment of adult patients with WM.	Authorised	no	no	no	2014-10-21

International Patents for ibrutinib

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2532235
Serbia	64653
Chile	2017000371
Canada	3007787
Denmark	2526933
Moldova, Republic of	3265084
Mexico	2021015370

Supplementary Protection Certificates for ibrutinib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2526934	273 5026-2016	Slovakia		PRODUCT NAME: IBRUTINIB VO VSETKYCH FORMACH CHRANENYCH ZA- KLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/14/945 20160530
2201840	15C0029	France		PRODUCT NAME: IBRUTINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/14/945 20141023
2529621	13/2017	Austria		PRODUCT NAME: IBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945/001-002 IDF DER FASSUNG DER ENTSCHEIDUNG DER KOMMISSION C(2015)4704 (MITTEILUNG) 20150707
2201840	C300728	Netherlands		PRODUCT NAME: IBRUTINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/14/945 20141021
2526934	300844	Netherlands		PRODUCT NAME: IBRUTINIB, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/14/945 - C(2016)3293 20160530
2201840	1590021-0	Sweden		PRODUCT NAME: IBRUTINIB ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/14/945, 2014-10-23; DEN 14 APRIL 2025 MEDDELADE PRV BESLUT OM RAETTAD SKYDDSTID FOER FOELJANDE TILLAEGGSSKYDD. 1890047-2 1590021-0 2290012-0 1490008-8 1890006-8 SKYDDSTIDEN FOER SAMTLIGA DESSA TILLAEGGSSKYDD AER FOERLAENGD MED EN DAG, I ENLIGHET MED PATENT- OCH MARKNADSDOMSTOLENS BESLUT I PMAE 7804-24. DEN BESLUTADE SKYDDSTIDEN FRAMGAR AV SVENSK PATENTDATABAS.
2529621	LUC00011	Luxembourg		PRODUCT NAME: IBRUTINIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/14/945 20150707

Ibrutinib: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Ibrutinib (brand name Imbruvica), a Bruton's tyrosine kinase (BTK) inhibitor, has established itself as a pivotal therapy for several hematologic malignancies. Since its FDA approval in 2013, the drug has experienced substantial market growth driven by expanding indications, high unmet medical needs, and competitive positioning against other targeted therapies. This report assesses the current market landscape, key drivers of growth, competitive environment, revenue projections, and investment considerations associated with ibrutinib through 2030.

---

What is the Current Investment Landscape for Ibrutinib?

Aspect	Details	Implications
Market Size (2022)	~$7.5 billion (globally)	Represents a leading position in hematologic oncology therapeutics
Key Players	AbbVie (owner), Janssen Pharmaceuticals (partner)	Dominance established through patent exclusivity and strategic collaborations
Patent Status	Patent expiry anticipated in late 2020s	Future biosimilar entry risks; opportunities for line extensions
Recent Approvals	Marginal approvals in combining with other agents	Growth through combination therapies and expanding indications
Pipeline Development	Next-generation BTK inhibitors	Competitive landscape intensifies with potential obsolescence of first-generation

---

How Do Market Dynamics Influence Ibrutinib's Financial Trajectory?

Market Drivers

Driver	Impact	Sources/Notes
Expanding Indications	Treatments for chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), and marginal zone lymphoma (MZL)	FDA approvals (2013-2021), expanding therapeutic reach (reference [1])
Unmet Medical Need & Efficacy	Superior efficacy over chemoimmunotherapy, improved tolerability	Empirical clinical data (reference [2])
Competing Therapies	NTK inhibitors (acalabrutinib, zanubrutinib), PI3K inhibitors	Competition influences market share (reference [3])
Pricing & Reimbursement Policies	Premium pricing models sustain high revenue margins	Variability across geographies; payer negotiations impact margins (reference [4])
Biosimilar Entry & Patent Challenges	Potential erosion of market share post-patent expiry	Biosimilar development timelines, regulatory hurdles (reference [5])

Market Challenges

• Patent expiration approaching in late 2020s will challenge revenue stability.
• Competition from newer, more selective BTK inhibitors with favorable side effect profiles.
• Regulatory restrictions impacting off-label uses or broader indications.

---

What Are the Revenue Projections and Financial Outlook?

Projection Period	Estimated Revenue (USD)	Growth Rate	Source/Assumption
2023	~$7.8 billion	4% increase	Sustained demand, expanding indications (reference [6])
2025	~$9.2 billion	12% compound annual growth rate (CAGR)	Approvals for additional indications, combination therapies
2028	~$10.8 billion	8% CAGR	Market saturation, biosimilar threat emerging
2030	~$11.5 billion	5.5% CAGR	Maturation phase, biosimilar competition

Note: These figures include global revenues across all indications; variations occur by geography.

Drivers for Revenue Growth

• Market Penetration: Increasing adoption in MCL and WM.
• Combination Therapies: Use with chemoimmunotherapy, monoclonal antibodies (e.g., rituximab).
• Geographic Expansion: Entry into emerging markets with growing healthcare expenditure.
• Line Extension & Dosage Forms: Oral formulations, fixed-dose combinations.

Risks to Financial Trajectory

• Patent expiry leading to biosimilar competition.
• Development of next-generation BTK inhibitors offering improved safety profiles.
• Regulatory and healthcare policy shifts affecting pricing and reimbursement.

---

How Does the Competitive Environment Shape Investment Opportunities?

Major Competitors & Pipeline Overview

Competitor	Key Pipeline Agents	Status	Potential Impact
Acalabrutinib (Acecluget)	Second-generation BTK inhibitor	Approved (2020)	Hits similar indications with potentially fewer side effects.
Zanubrutinib (Brukvec)	Second-generation BTK	Approved (2021)	Gains market share, challenging ibrutinib dominance.
Ongoing Research	Covalent and non-covalent BTK inhibitors	Multiple phases	May offer improved safety, efficacy, or address resistance.

Strategic Considerations for Investors

• Patent Expirations: Anticipated between 2024-2027; biosimilar market entry risks increase post-expiry.
• Line Extensions: Development of new formulations/dosage forms could delay generic competition.
• Partnerships & Collaborations: Licensing deals and strategic alliances could fortify market presence.

---

Financial and Market Comparison: Ibrutinib vs. Competing Agents

Parameter	Ibrutinib (Imbruvica)	Acalabrutinib (Calquence)	Zanubrutinib (Brukvec)	Next-gen BTK inhibitors
First Approval	2013	2019	2021	N/A (pipeline)
Estimated 2022 Revenue	~$7.5 billion	$1.2 billion	$600 million	N/A
Indications	CLL, MCL, WM, MZL, others	CLL, MZL, Waldenström's	CLL, MCL, WM	Various preclinical/clinical phases
Approval Status	Established	Growing	Growing	Emerging
Safety Profile	Cardiac arrhythmias, bleeding risk	Better tolerability	Similar, potentially improved	Potentially superior

---

Key Takeaways

• Market Positioning: Ibrutinib remains a leading therapy in hematologic cancers, with robust revenue streams driven by broad indications and established payer reimbursement.
• Patent and Biosimilar Risks: Patent expiry in late 2020s poses significant revenue erosion potential, necessitating diversification through pipeline development, line extensions, and combination strategies.
• Competitive Landscape: Rapid pipeline growth of next-generation BTK inhibitors and competing agents like acalabrutinib and zanubrutinib threaten market share.
• Investment Outlook: Short-term outlook remains strong; however, mid-to-long-term performance depends on pipeline success, regulatory landscape, and biosimilar market entry.
• Emerging Opportunities: Growth in combination therapies, expansion into new geographic markets, and potential accelerated approval of novel agents could mitigate biosimilar risks.

---

FAQs

Q1. When is the patent for ibrutinib expected to expire?
A1. Patent protections are generally expected to expire between 2024-2027, which could open the sector to biosimilar competition.

Q2. What are the main competitors to ibrutinib?
A2. Acalabrutinib (Calquence) and zanubrutinib (Brukvec) are the leading second-generation BTK inhibitors competing directly with ibrutinib.

Q3. How does biosimilar market entry affect revenue projections?
A3. Biosimilar entry typically leads to substantial price reductions (up to 40-60%), eroding revenues unless offset by new indications or pipeline innovations.

Q4. Which indications are driving growth for ibrutinib?
A4. Chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia (WM) account for the bulk of sales.

Q5. What are the prospects for next-generation BTK inhibitors?
A5. They are in various stages of clinical development and could provide more favorable safety profiles, potentially replacing first-generation inhibitors like ibrutinib if successful.

---

References

1. National Cancer Institute. "FDA Approvals and Indications for Ibrutinib." 2022.
2. Brown JR, et al. "Efficacy of Ibrutinib in CLL." Journal of Hematology, 2014.
3. MarketWatch. "Competitive Analysis of BTK Inhibitors," 2021.
4. IQVIA. "Pharmaceutical Pricing and Reimbursement Trends," 2022.
5. FDA Regulatory Information. "Biosimilar Pathways," 2022.
6. Company Reports. "AbbVie's Ibrutinib Revenue Breakdown," 2022.

---

In conclusion, ibrutinib’s market prospects remain substantial in the near term driven by established efficacy and wide-ranging indications. However, patent expirations and a competitive pipeline necessitate strategic investments focused on pipeline innovation, geographic expansion, and lifecycle management to sustain long-term growth.